Navigation Links
VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results
Date:11/7/2011

MOUNTAIN VIEW, Calif., Nov. 7, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the third quarter and nine months ended September 30, 2011.

Third Quarter ResultsFor the third quarter ended September 30, 2011, VIVUS reported a net loss of $8.6 million, or $0.10 net loss per share, as compared to a net loss of $18.0 million, or $0.22 net loss per share for the third quarter of 2010.  The net loss from continuing operations was $8.8 million, or $0.10 net loss per share, as compared to a net loss from continuing operations of $18.1 million, or $0.22 net loss per share during the third quarter of 2010.  The lower net loss in 2011 as compared to 2010 primarily results from reduced research and development spending on Qnexa® and avanafil as these projects progress from the clinical trial stage to the regulatory review stage.  

In the third quarter of 2011, we closed on a registered direct offering of our common stock which provided us with gross proceeds of $45.8 million before deduction of fees and expenses related to the offering.

First Nine Months ResultsNet loss for the first nine months of 2011 was $34.7 million, or $0.42 net loss per share, as compared to a net loss of $59.6 million, or $0.74 net loss per share for 2010.  The decrease in net loss in the first nine months of 2011 as compared to 2010 results primarily from reduced research and development spending on Qnexa and avanafil.  In addition, the net loss for the first nine months last year included a $3.2 million loss from discontinued operations of the MUSE business, which was sold in the fourth quarter 2010.

Cash, Cash Equivalents and Available-for-Sale SecuritiesVIVUS had cash, cash equivalents and available-
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. VIVUS to Present at the BioCentury NewsMakers Conference
2. VIVUS to Participate in Three Investor Conferences in September
3. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
4. VIVUS Reports First Quarter 2011 Financial Results
5. VIVUS to Present at Four Upcoming Investor Conferences in May
6. VIVUS to Present at the 10th Annual Needham Healthcare Conference
7. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
8. VIVUS to Present at Four Upcoming Investor Conferences
9. VIVUS to Present at Two Upcoming Investor Conferences
10. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
11. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... A leading manufacturer of stainless steel tanks and ... custom fabrication services today at INTERPHEX 2015. The company ... prior to the INTERPHEX event. The expo takes place ... at the Javits Center in New York City, where ... most innovative pharmaceutical and biotech firms will be in ...
(Date:4/20/2015)... -- Stent retriever thrombectomy, an endovascular technique that ... reduced disability after stroke, according to a groundbreaking ... the Society of Vascular and Interventional Neurology (SVIN).  ... forward that will change the way we approach ... who is associate professor of Neurology and Neurosurgery ...
(Date:4/20/2015)... April 20, 2015 Orthobiologics are ... bone injuries. The orthobiologics market is a rewarding market, ... stakeholders. The global orthobiologics market report defines and segments ... The global orthobiologics market was valued at $5,712.4 million ... by 2019, at a CAGR of 6.7% from 2014 ...
(Date:4/20/2015)... INDIANAPOLIS , April 20, 2015  Eli Lilly ... stage data from several targeted cancer therapies, reflecting Lilly,s ... Research (AACR) Annual Meeting 2015, held April 18-22 in ... "Bringing Cancer Discoveries to Patients" is the theme of ... through Lilly,s commitment to broadening its portfolio of therapies ...
Breaking Biology Technology:HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6
... - Conference Call to Discuss Results to Be Held at ... Incorporated,s (Nasdaq: VPHM ) first quarter financial results ... 29, 2009 before the open of the U.S. financial markets.The ... at 9:00 a.m. Eastern Time on the same day. ...
... Human Tissue Collection and Specimen Management Provide FocusMEMPHIS, ... the physician partners of Accelerated Community Oncology Research ... (USA), has begun acquiring human tissue samples for ... World BioBank supports biomarker storage in conjunction with ...
... Calif., April 22 Metabolex, Inc., a biopharmaceutical company ... therapeutics for the treatment of diabetes and related metabolic ... to its Board of Directors. Mr. von Emster currently ... November 2000 to March 2009, Mr. von Emster was ...
Cached Biology Technology:ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2World BioBank(TM) Launch Benefits Advanced Medical Research 2World BioBank(TM) Launch Benefits Advanced Medical Research 3Metabolex Announces Election of Kurt von Emster to Board of Directors 2
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... that freezing kidney tumors through percutaneous cryoablation shows promise ... Their early findings showing short-term success in more ... this month’s issue of Radiology. , The standard treatment ... of a long-term cure. For some patients, surgery ...
... Medicine has helped confirm the reliability of a new ... long-promised era of personalized medicine based on each individual's ... five sites that helped determine that the genetic test ... developing cirrhosis from chronic hepatitis C infection. That means ...
... A study of eight hospitals in Peru has shown ... double that of mechanically ventilated negative-pressure rooms and 18 ... , The researchers, led by Rod Escombe from ... ventilated clinical rooms such as respiratory isolation rooms, TB ...
Cached Biology News:Cryoablation -- A new treatment option for some kidney tumor patients 2Cryoablation -- A new treatment option for some kidney tumor patients 3New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3
P8B1...
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Biology Products: